Interplay between metabolism and transport of resveratrol

Annals of the New York Academy of Sciences

Volumn 1290, Issue 1, 2013, Pages 98-106

  Maier Salamon, Alexandra ^a   Böhmdorfer, Michaela ^a   Riha, Juliane ^a   Thalhammer, Theresia ^b   Szekeres, Thomas ^b   Jaeger, Walter ^a  

^a UNIVERSITY OF VIENNA   (Austria)

^b MEDICAL UNIVERSITY OF VIENNA   (Austria)

Author keywords

ABC transporter; Metabolism; Resveratrol; Sulfatases

Indexed keywords

BREAST CANCER RESISTANCE PROTEIN; CYTOCHROME P450 2C9; CYTOCHROME P450 2D6; CYTOCHROME P450 3A4; ESTRADIOL; MESSENGER RNA; MULTIDRUG RESISTANCE PROTEIN 2; MULTIDRUG RESISTANCE PROTEIN 3; RESVERATROL; STERYL SULFATASE; SULFOTRANSFERASE;

ABDOMINAL PAIN; ARTICLE; BREAST TUMOR; CELL SPECIFICITY; CELL TRANSPORT; DIARRHEA; DRUG METABOLISM; DRUG SULFATION; DRUG TISSUE LEVEL; DRUG TRANSPORT; GASTROINTESTINAL SYMPTOM; HEARTBURN; HOT FLUSH; HUMAN; IN VITRO STUDY; LOW DRUG DOSE; NAUSEA; NEPHROTOXICITY; NONHUMAN; PROTEIN EXPRESSION; SINGLE DRUG DOSE; TISSUE SPECIFICITY; VOMITING;

EID: 84880365792     PISSN: 00778923     EISSN: 17496632     Source Type: Book Series    
DOI: 10.1111/nyas.12198     Document Type: Article

References (30)

1. Tome-Carneiro, J., M. Larrosa, M.J. Yanez-Gascon, et al. 2013. One-year supplementation with a grape extract containing resveratrol modulates inflammatory-related microRNAs and cytokines expression in peripheral blood mononuclear cells of type 2 diabetes and hypertensive patients with coronary artery disease. Pharmacol. Res. 72: 69-82.
2. Patel, K.R., V.A. Brown, D.J. Jones, et al. 2010. Clinical pharmacology of resveratrol and its metabolites in colorectal cancer patients. Cancer Res. 70: 7392-7399.
3. Tomic, J., L. McCaw, Y. Li, et al. 2013. Resveratrol has anti-leukemic activity associated with decreased O-Glcnated poteins. Exp. Hematol. Epub ahead of print in press.
4. Chow, H.H., L.L. Garland, C.H. Hsu, et al. 2010. Resveratrol modulates drug- and carcinogen-metabolizing enzymes in a healthy volunteer study. Cancer Prev. Res. 3: 1168-1175.
5. Shin, S., J.H. Jeon, D. Park, et al. 2008. Trans-resveratrol relaxes the corpus cavernosum ex vivo and enhances testosterone levels and sperm quality in vivo. Arch. Pharm. Res. 31: 83-87.
6. Ung, D. & S. Nagar. 2009. Trans-resveratrol-mediated inhibition of beta-oestradiol conjugation in MCF-7 cells stably expressing human sulfotransferases SULT1A1 or SULT2E1, and human liver microsomes. Xenobiotica 39: 72-79.
7. Boocock, D.J., G.E. Faust, K.R. Patel, et al. 2007. Phase I dose escalation pharmacokinetic study in healthy volunteers of resveratrol, a potential cancer chemopreventive agent. Cancer Epidemiol. Biomarkers Prev. 16: 1246-1252.
8. Burkon, A. & V. Somoza. 2008. Quantification of free and protein-bound trans-resveratrol metabolites and identification of trans-resveratrol-C/O-conjugated diglucuronides: two novel resveratrol metabolites in human plasma. Mol. Nutr. Food Res. 52: 549-557.
9. Rotches-Ribalta, M., M. Urpi-Sarda, R. Llorach, et al. 2012. Gut and microbial resveratrol metabolite profiling after moderate long-term consumption of red wine versus dealcoholized red wine in humans by an optimized ultra-high-pressure liquid chromatography tandem mass spectrometry method. J. Chromatogr. A 1265: 105-113.
10. Brown, V.A., K.R. Patel, M. Viskaduraki, et al. 2010. Repeat dose study of the cancer chemopreventive agent resveratrol in healthy volunteers: safety, pharmacokinetics, and effect on the insulin-like growth factor axis. Cancer Res. 70: 9003-9011.
11. Maier-Salamon, A., B. Hagenauer, M. Wirth, et al. 2006. Increased transport of resveratrol across monolayers of the human intestinal Caco-2 cells is mediated by inhibition and saturation of metabolites. Pharm. Res. 23: 2107-2115.
12. Maier-Salamon, A., M. Böhmdorfer, T. Thalhammer, et al. 2011. Hepatic glucuronidation of resveratrol: interspecies comparison of enzyme kinetic profiles in humans, mouse, rat and dog. Drug Metab. Phamacokinet. 26: 364-373.
13. Hoshino, J., E.J. Park, T.P. Kondratyuk, et al. 2010. Selective synthesis and biological evaluation of sulfate-conjugated resveratrol metabolites. J. Med. Chem. 53: 5033-5043.
14. Calamini, B., K. Ratia, M.G. Malkowski, et al. 2010. Pleiotropic mechanisms facilitated by resveratrol and its metabolites. Biochem. J. 429: 273-282.
15. Herath, W., S.I. Khan & I.A. Khan. 2012. Microbial metabolism. Part 14. Isolation and bioactivity evaluation of microbial metabolites of resveratrol. Nat. Prod. Res. 1-8, iFirst.
16. Ruotolo, R., L. Calani, E. Fietta, et al. 2013. Anti-estrogenic activity of a human resveratrol metabolite. Nutr. Metab. Cardiovasc. Epub ahead of print in press.
17. Lasa, A., I. Churruca, I. Eseberri, et al. 2012. Delipidating effect of resveratrol metabolites in 3T3-L1 adipocytes. Mol. Nutr. Food Res. 56: 1559-1568.
18. Miksits, M., K. Wlcek, M. Svoboda, et al. 2009. Antitumor activity of resveratrol and its sulfated metabolites against human breast cancer cells. Planta Med. 75: 1-4.
19. Polycarpou, E., L.B. Meira, S. Carrington, et al. 2013. Resveratrol 3-O-d-glucuronide and resveratrol 4′-O-d-glucuronide inhibit colon cancer cell growth: evidence for a role of A3 adenosine receptors, cyclin D1 depletion, and G1 cell cycle arrest. Mol. Nutr. Food Res. Epub ahead of print in press.
20. Miksits, M., K. Wlcek, M. Svoboda, et al. 2010. Expression of sulfotransferases and sulfatases in human breast cancer: impact on resveratrol metabolism. Cancer Lett. 289: 237-245.
21. Sun, Z., H. Li, X.H. Shu, et al. 2012. Distinct sulfonation activities in resveratrol-sensitive and resveratrol-insensitive human glioblastoma cells. FEBS J. 279: 2381-2392.
22. Howell, L.M., D.P. Berry, P.J. Elliot, et al. 2011. Phase I randomized, double-blind pilot study of micronized resveratrol (SRT501) in patients with hepatic metastases-safety, pharmacokinetics, and pharmacodynamics. Cancer Prev. Res. 4: 1419-1425.
23. Azorin-Ortuno, M., M.J. Yanez-Gascon, F. Vallejo, et al. 2011. Metabolites and tissue distribution of resveratrol in the pig. Mol. Nutr. Food Res. 55: 1154-1168.
24. Maier-Salamon, A., B. Hagenauer, G. Reznicek, et al. 2009. Metabolism and disposition of resveratrol in the isolated perfused rat liver: role of Mrp2 in the biliary excretion of glucuronides. J. Pharm. Sci. 98: 3839-3849.
25. Breedveld, P., D. Pluim, G. Cipriani, et al. 2007. The effect of low pH on breast cancer resistance protein (ABCG2)-mediated transport of methotrexate, 7-hydroxymethotrexate, methotrexate diglutamate, folic acid, mitoxantrone, topotecan, and resveratrol in in vitro drug transport models. Mol. Pharmacol. 71: 240-249.
26. Van de Wetering, K., A. Burkon, W. Feddema, et al. 2009. Intestinal breast cancer resistance protein (BCRP)/Bcrp1 and multidrug resistance protein 3 (MRP3)/Mrp2 are involved in the pharmacokinetics of resveratrol. Mol. Pharmacol. 75: 876-885.
27. 14C]-trans-resveratrol, a cancer chemopreventive polyphenol, in mouse tissues after oral administration. Life Sci. 72: 2219-2233.
28. Juan, M.E., M. Maijó & J.M. Planas. 2009. Quantification of trans-resveratrol and its metabolites in rat plasma and tissues by HPLC. J. Pharm. Biomed. Anal. 51: 391-398.
29. Alfaras, I., M. Peruez, M.E. Juan, et al. 2010. Involvement of breast cancer resistance protein (BCRP1/ABCG2) in the bioavailability and tissue distribution of trans-resveratrol in knockout mice. J. Agric. Food. Chem. 58: 4523-4528.
30. Fong, Y.K., C.R. Li, S.K. Wo, et al. 2012. In vitro and in situ evaluation of herb-drug interactions during intestinal metabolism and absorption of baicalein. J. Ethnopharmacol. 141: 742-753.